Insiders · MACK

Eric Andersen

Director at Merrimack Pharmaceuticals Inc (MACK)

Eric Andersen has filed 16 insider reports with the SEC since April 2021, as director at Merrimack Pharmaceuticals Inc (MACK). Eric Andersen made no open-market purchases or sales in the last 12 months. In the latest amended filing, on December 28, 2023, Eric Andersen bought 49,550 shares of Merrimack Pharmaceuticals Inc (MACK) for $652K at an average of $13.15.

Filings
16
Companies
1
Bought on market
$12.5M
Sold on market
$338K

Companies where Eric Andersen is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Merrimack Pharmaceuticals Inc logo
MACK
Merrimack Pharmaceuticals Inc
Director$12.5M$338K$10.86Dec 28, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Eric Andersen with

Questions about Eric Andersen

What is Eric Andersen's role at Merrimack Pharmaceuticals Inc?
Eric Andersen reports to the SEC as director at Merrimack Pharmaceuticals Inc (MACK), according to the latest filing on December 28, 2023.
Has Eric Andersen bought or sold stock recently?
The most recent open-market purchase was on December 28, 2023: bought 49,550 shares of Merrimack Pharmaceuticals Inc (MACK) for $652K at an average of $13.15. The most recent open-market sale was on July 1, 2021: sold 52,914 shares of Merrimack Pharmaceuticals Inc (MACK) for $338K at an average of $6.39.
How do I get alerts when Eric Andersen files?
Follow Eric Andersen on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Eric Andersen (SEC CIK 0001517667). Totals count each trade once, skipping amendments whose original is on file, from Apr 14, 2021 on. View on SEC EDGAR